Autres langues ORION Corp.

Actions

A271560

KR7271560005

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
93 500 ^KRW	+1,52 %		+3,54 %	-19,47 %

13/03	ORION Corp. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
2023	ORION Corp. annonce ses résultats pour le troisième trimestre et les neuf mois terminés le 30 septembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ORION Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Orion Set to Acquire 25% Stake in LegoChem Biosciences	17/01
Orion Temporarily Resumes Production of Discontinued Snacks to Offer Young Patients	10/01
ORION Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Celcuity to Proceed With Phase 1b/2 Trial of Gedatolisib Plus Nubeqa, Signs Supply Agreement With Bayer	22/08/23
ORION Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Marinus Pharmaceuticals Says European Commission Approves Ztalmy Oral Suspension	31/07/23
Orion Corporation Announces European Commission Approval of Ztalmy(R) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder	31/07/23
ORION Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
EU empfiehlt weitere Indikation für Bayer-Krebsmittel Nubeqa	27/01/23
Orion Corporation and Amneal Pharmaceuticals, Inc. Sign License Agreement with Amneal Pharmaceuticals, Inc. to Commercialise Amneal's Generic Products in Europe, Australia and New Zealand	04/01/23
South Korean Snack Maker Orion Temporarily Closes Tmall Flagship Store	27/12/22
FDA prüft neue Indikation für Bayer-Krebsmittel Nubeqa beschleunigt	03/05/22
Orion Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU	18/02/22
Infosys Selected by Finland-Based Orion to Help Transform Its ERP, Planning Platforms	14/12/21
Orion's Net Attributable Income Declines 4.3% in September Quarter	11/11/21
Marinus Pharmaceuticals Submits NDA to FDA for Seizure Treatment	03/08/21
China's Economy Powers Ahead While the Rest of the World Reels	13/01/21
Lotus Pharma and Orion to Enter into Marketing and Distribution Agreement	31/12/19
Oriola and Orion Renew Their Distribution Agreement in Finland	28/08/19

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ORION Corp.

Actions

A271560

KR7271560005

Autres langues

Filtres